These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
119 related articles for article (PubMed ID: 37805836)
1. Utilization of Antiviral Therapy for Patients With Hepatitis B-Related Hepatocellular Carcinoma: A Nationwide Real-World US Study. Kudaravalli S; Kam LY; Huang DQ; Cheung R; Nguyen MH Clin Gastroenterol Hepatol; 2023 Dec; 21(13):3305-3313.e4. PubMed ID: 37805836 [TBL] [Abstract][Full Text] [Related]
2. Reduced Incidence of Hepatocellular Carcinoma in Cirrhotic and Noncirrhotic Patients With Chronic Hepatitis B Treated With Tenofovir-A Propensity Score-Matched Study. Nguyen MH; Yang HI; Le A; Henry L; Nguyen N; Lee MH; Zhang J; Wong C; Wong C; Trinh H J Infect Dis; 2019 Jan; 219(1):10-18. PubMed ID: 29982737 [TBL] [Abstract][Full Text] [Related]
3. Treatment rates and factors associated with direct-acting antiviral therapy for insured patients with hepatitis C-related hepatocellular carcinoma - A real-world nationwide study. Kam LY; Yeo YH; Ji F; Henry L; Cheung R; Nguyen MH Aliment Pharmacol Ther; 2024 Feb; 59(3):350-360. PubMed ID: 37937485 [TBL] [Abstract][Full Text] [Related]
4. Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. Yang HI; Yeh ML; Wong GL; Peng CY; Chen CH; Trinh HN; Cheung KS; Xie Q; Su TH; Kozuka R; Lee DH; Ogawa E; Zhao C; Ning HB; Huang R; Li J; Zhang JQ; Ide T; Xing H; Iwane S; Takahashi H; Wong C; Wong C; Lin CH; Hoang J; Le A; Henry L; Toyoda H; Ueno Y; Gane EJ; Eguchi Y; Kurosaki M; Wu C; Liu C; Shang J; Furusyo N; Enomoto M; Kao JH; Yuen MF; Yu ML; Nguyen MH J Infect Dis; 2020 Jan; 221(3):389-399. PubMed ID: 31550363 [TBL] [Abstract][Full Text] [Related]
5. Antiviral therapy for chronic hepatitis B virus infection and development of hepatocellular carcinoma in a US population. Gordon SC; Lamerato LE; Rupp LB; Li J; Holmberg SD; Moorman AC; Spradling PR; Teshale EH; Vijayadeva V; Boscarino JA; Henkle EM; Oja-Tebbe N; Lu M; Clin Gastroenterol Hepatol; 2014 May; 12(5):885-93. PubMed ID: 24107395 [TBL] [Abstract][Full Text] [Related]
6. Antiviral Therapy Utilization and 10-Year Outcomes in Resected Hepatitis B Virus- and Hepatitis C Virus-Related Hepatocellular Carcinoma. Huang DQ; Hoang JK; Kamal R; Tsai PC; Toyoda H; Yeh ML; Yasuda S; Leong J; Maeda M; Huang CF; Won Jun D; Ishigami M; Tanaka Y; Uojima H; Ogawa E; Abe H; Hsu YC; Tseng CH; Alsudaney M; Yang JD; Yoshimaru Y; Suzuki T; Liu JK; Landis C; Dai CY; Huang JF; Chuang WL; Schwartz M; Dan YY; Esquivel C; Bonham A; Yu ML; Nguyen MH J Clin Oncol; 2024 Mar; 42(7):790-799. PubMed ID: 38175991 [TBL] [Abstract][Full Text] [Related]
7. Hepatitis B Virus-related Care Quality in Patients With Hepatitis B/Human Immunodeficiency Virus Coinfection Versus Hepatitis B Monoinfection: A National Cohort Study. Lee TH; Hunt CM; Maier MM; Lowy E; Beste LA Clin Infect Dis; 2022 Oct; 75(9):1529-1536. PubMed ID: 35349635 [TBL] [Abstract][Full Text] [Related]
8. Post-operative recurrence of liver cancer according to antiviral therapy for detectable hepatitis B viremia: A nationwide study. Yun B; Ahn SH; Oh J; Yoon JH; Kim BK Eur J Intern Med; 2023 Jan; 107():66-72. PubMed ID: 36347739 [TBL] [Abstract][Full Text] [Related]
9. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends. Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387 [TBL] [Abstract][Full Text] [Related]
10. Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience. Chen VL; Yeh ML; Le AK; Jun M; Saeed WK; Yang JD; Huang CF; Lee HY; Tsai PC; Lee MH; Giama N; Kim NG; Nguyen PP; Dang H; Ali HA; Zhang N; Huang JF; Dai CY; Chuang WL; Roberts LR; Jun DW; Lim YS; Yu ML; Nguyen MH Aliment Pharmacol Ther; 2018 Jul; 48(1):44-54. PubMed ID: 29797518 [TBL] [Abstract][Full Text] [Related]
11. Verification of hepatitis B-related hepatocellular carcinoma predictive models to evaluate the risk of HCC in patients with liver cirrhosis under antiviral treatment. Huang X; Wang H; Zhang W; Gu E Eur J Gastroenterol Hepatol; 2022 May; 34(5):546-552. PubMed ID: 35170528 [TBL] [Abstract][Full Text] [Related]
12. Antiviral Therapy Reduces Risk of Cirrhosis in Noncirrhotic HBV Patients Among 4 Urban Safety-Net Health Systems. Wong RJ; Jain MK; Therapondos G; Niu B; Kshirsagar O; Thamer M Am J Gastroenterol; 2021 Jul; 116(7):1465-1475. PubMed ID: 33661148 [TBL] [Abstract][Full Text] [Related]
13. Hepatocellular carcinoma progression in hepatitis B virus-related cirrhosis patients receiving nucleoside (acid) analogs therapy: A retrospective cross-sectional study. Yang DH; Wang WP; Zhang Q; Pan HY; Huang YC; Zhang JJ World J Gastroenterol; 2021 May; 27(17):2025-2038. PubMed ID: 34007137 [TBL] [Abstract][Full Text] [Related]
14. Liver Cirrhosis, Not Antiviral Therapy, Predicts Clinical Outcome in Cohorts with Heterogeneous Hepatitis B Viral Status. Kim MN; Hwang SG; Kim BK; Park JY; Kim DY; Han KH; Kim SU; Ahn SH Gut Liver; 2019 Mar; 13(2):197-205. PubMed ID: 30602075 [TBL] [Abstract][Full Text] [Related]
15. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK; Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118 [TBL] [Abstract][Full Text] [Related]
16. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients. Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH; Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134 [TBL] [Abstract][Full Text] [Related]
17. Differential characteristics and outcomes of Asian and non-Asian patients with HBV-related hepatocellular carcinoma. Huang DQ; Hoang JK; Leong J; Riveiro-Barciela M; Maeda M; Yang JD; Accarino EV; Thin K; Trinh L; Cheung RC; Roberts LR; Buti M; Schwartz M; Nguyen MH Liver Int; 2021 Aug; 41(8):1922-1932. PubMed ID: 33713386 [TBL] [Abstract][Full Text] [Related]
18. Hepatitis B Virus Combo Mutations Improve the Prediction and Active Prophylaxis of Hepatocellular Carcinoma: A Clinic-Based Cohort Study. Yin J; Wang J; Pu R; Xin H; Li Z; Han X; Ding Y; Du Y; Liu W; Deng Y; Ji X; Wu M; Yu M; Zhang H; Wang H; Thompson TC; Ni W; Cao G Cancer Prev Res (Phila); 2015 Oct; 8(10):978-88. PubMed ID: 26290395 [TBL] [Abstract][Full Text] [Related]
19. Long-term follow-up of cumulative incidence of hepatocellular carcinoma in hepatitis B virus patients without antiviral therapy. Jiang XY; Huang B; Huang DP; Wei CS; Zhong WC; Peng DT; Huang FR; Tong GD World J Gastroenterol; 2021 Mar; 27(11):1101-1116. PubMed ID: 33776376 [TBL] [Abstract][Full Text] [Related]
20. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B. Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ J Viral Hepat; 2018 May; 25(5):552-560. PubMed ID: 29194870 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]